Humana (HUM) Stock Tumbles Despite Q1 Earnings Beat Amid Unchanged Guidance
Humana Inc., HUM The company reported adjusted earnings of $10.31 per share, surpassing Wall Streets consensus estimate of approximately $10.19–$10.20. Revenue climbed to $39.65 billion from $32.11 billion in the prior-year period, also exceeding the anticipated $39.37 billion. However, the positive earnings surprise failed to boost investor confidence. $HUM Q1 2026 earnings: Massive Growth Masks a Severe Earnings Reset Humanas 23% YoY revenue surge looks impressive on the surface, driven by an accelerating influx of 1.1 million new Individual Medicare Advantage (MA) members in Q1. However, this volume is not reaching the… — Finsee (@Finsee_main) April 29, 2026 According to Julie Utterback, an analyst at Morningstar, market participants likely anticipated that Humana would increase its forward guidance following such a robust quarterly performance. Instead, the company stood pat. Management reaffirmed its full-year adjusted earnings projection of at least $9 per share. Notably, the reported earnings outlook was actually lowered — revised down to at least $8.36 per share from the prior expectation of at least $8.89. This downward revision accounts for expenses associated with a multiyear restructuring initiative, encompassing severance payments, asset write-downs, and external consulting fees. Star Rating Decline Pressures Profitability Central to Humanas challenges are its diminished Medicare Advantage Star Ratings for 2026. These government-issued ratings, ranging from